Form 4: Zoetis EVP Sarbaugh Reports Routine Stock Transactions

Zoetis Executive Vice President Keith Sarbaugh reported the acquisition of common stock from restricted stock unit vesting and subsequent disposition for tax purposes.

Summary

• Keith Sarbaugh, Executive Vice President of Zoetis Inc., reported transactions on February 19, 2026.
• Acquired 386 shares of common stock upon the vesting and settlement of restricted stock units (RSUs).
• Disposed of 154 shares of common stock at a price of $127.28 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Sarbaugh beneficially owns 2,342 shares of Zoetis Inc. common stock directly.
• Remaining derivative securities (Restricted Stock Units) include 773, 2,674, 120, and 1,528.0167 units, each representing a contingent right to receive one share of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine and expected transaction related to executive compensation, reflecting the vesting of previously granted equity and standard tax withholding, which is neutral to slightly positive as it indicates continued executive alignment.

Positives

• Executive Vice President Keith Sarbaugh acquired 386 shares of common stock through the vesting of restricted stock units, indicating a realization of equity compensation and continued alignment with shareholder interests.

Negatives

• Disposition of 154 shares of common stock at $127.28 per share for tax withholding purposes reduced the direct beneficial ownership of common stock.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to equity compensation vesting and subsequent tax-related sales, are common across industries. This specific filing reflects a routine compensation event for a senior executive at Zoetis, a leading animal health company, and is consistent with standard executive incentive structures.

Comparison to Industry Standards

• The vesting and subsequent tax-related sale of restricted stock units for executives is a common practice in publicly traded companies, aligning executive incentives with shareholder value over time. This transaction is consistent with typical equity compensation structures seen in the pharmaceutical and animal health sectors, such as those at competitors like Elanco Animal Health (ELAN) or Merck Animal Health (MRK's animal health division).

Stakeholder Impact

• Shareholders: The disposition of shares for tax purposes slightly increases the public float, but the overall impact is minimal as it's a routine compensation event. The vesting of RSUs aligns executive interests with long-term shareholder value.
• Employees: Reflects the company's ongoing equity compensation program for executives, which is a standard component of executive remuneration.

Next Steps

• Future vesting of remaining restricted stock units will occur on their respective anniversary dates, subject to the reporting person's continued service through such vesting dates.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of restricted stock units and a subsequent sale to cover tax obligations. Such transactions are standard and do not typically indicate a change in the company's fundamental performance or outlook. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an existing investment thesis.

Keywords

Zoetis, ZTS, Form 4, Insider Trading, Restricted Stock Units, Equity Compensation, Executive Stock Transactions, Keith Sarbaugh